Suppr超能文献

口服司美格鲁肽可改善 2 型糖尿病患者的餐后血糖和脂代谢,并延缓胃排空。

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.

机构信息

Novo Nordisk A/S, Søborg, Denmark.

Covance Clinical Research Unit Ltd, Leeds, UK.

出版信息

Diabetes Obes Metab. 2021 Jul;23(7):1594-1603. doi: 10.1111/dom.14373. Epub 2021 Mar 29.

Abstract

AIM

To assess the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes (T2D).

MATERIALS AND METHODS

In this randomized, double-blind, single-centre, crossover trial, subjects with T2D received once-daily oral semaglutide (escalated to 14 mg) followed by placebo, or vice versa, over two consecutive 12-week periods. Glucose and lipid metabolism, and gastric emptying (paracetamol absorption) were assessed before and after two types of standardized meals (standard and/or fat-rich) at the end of each treatment period. The primary endpoint was area under the glucose 0-5-h curve (AUC ) after the standard breakfast.

RESULTS

Fifteen subjects were enrolled (mean age 58.2 years, HbA1c 6.9%, body weight 93.9 kg, diabetes duration 3.1 years; 13 [86.7%] males). Fasting concentrations of glucose were significantly lower, and C-peptide significantly greater, with oral semaglutide versus placebo. Postprandial glucose (AUC ) was significantly lower with oral semaglutide versus placebo (estimated treatment ratio, 0.71; 95% CI, 0.63, 0.81; p < .0001); glucose incremental AUC (iAUC ) and glucagon AUC were also significantly reduced, with similar results after the fat-rich breakfast. Fasting concentrations of triglycerides, very low-density lipoprotein (VLDL) and apolipoprotein B48 (ApoB48) were significantly lower with oral semaglutide versus placebo. AUC for triglycerides, VLDL and ApoB48, and triglycerides iAUC , were significantly reduced after oral semaglutide versus placebo. During the first postprandial hour, gastric emptying was delayed (a 31% decrease in paracetamol AUC ) with oral semaglutide versus placebo. One serious adverse event (acute myocardial infarction) occurred during oral semaglutide treatment.

CONCLUSION

Oral semaglutide significantly improved fasting and postprandial glucose and lipid metabolism, and delayed gastric emptying.

摘要

目的

评估口服司美格鲁肽对 2 型糖尿病(T2D)患者餐后血糖和血脂代谢及胃排空的影响。

材料和方法

在这项随机、双盲、单中心、交叉试验中,T2D 患者接受每日一次口服司美格鲁肽(递增至 14mg),随后是安慰剂,或反之,连续两个 12 周疗程。在每个治疗期结束时,在两种标准餐(标准餐和/或高脂肪餐)前后评估葡萄糖和血脂代谢及胃排空(对乙酰氨基酚吸收)。主要终点是标准早餐后 0-5 小时血糖曲线下面积(AUC)。

结果

共纳入 15 名受试者(平均年龄 58.2 岁,HbA1c 6.9%,体重 93.9kg,糖尿病病程 3.1 年;13 名[86.7%]男性)。与安慰剂相比,口服司美格鲁肽时空腹血糖浓度显著降低,C 肽浓度显著升高。与安慰剂相比,口服司美格鲁肽时餐后血糖(AUC)显著降低(估计治疗比为 0.71;95%CI,0.63,0.81;p<0.0001);餐后血糖增量 AUC(iAUC)和胰高血糖素 AUC 也显著降低,高脂肪早餐后也有类似结果。与安慰剂相比,空腹甘油三酯、极低密度脂蛋白(VLDL)和载脂蛋白 B48(ApoB48)浓度显著降低。与安慰剂相比,口服司美格鲁肽时甘油三酯、VLDL 和 ApoB48 的 AUC 和甘油三酯 iAUC 显著降低。口服司美格鲁肽时,胃排空在第一餐后小时延迟(对乙酰氨基酚 AUC 降低 31%)。口服司美格鲁肽治疗期间发生 1 例严重不良事件(急性心肌梗死)。

结论

口服司美格鲁肽可显著改善空腹和餐后血糖及血脂代谢,并延迟胃排空。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77f0/8251575/11aad08e47df/DOM-23-1594-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验